Clinical Trial Update: Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Asacol 4.8 g/day (800 mg tablets) for active ulcerative colitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Asacol (mesalamine)

Snippet

Sponsor: Tillotts Pharma AG | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2017-04-24